Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $81.8 million.

  • Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) rose 2313.22% to $81.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.8 million, marking a year-over-year increase of 2313.22%. This contributed to the annual value of $67.9 million for FY2024, which is 5168.16% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) is $81.8 million, which was up 2313.22% from $81.6 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) ranged from a high of $81.8 million in Q3 2025 and a low of $6.3 million during Q1 2021
  • Its 5-year average for Shares Outstanding (Weighted Average) is $44.0 million, with a median of $43.3 million in 2023.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 31232.1% in 2022, then skyrocketed by 2313.22% in 2025.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) stood at $11.9 million in 2021, then skyrocketed by 169.22% to $32.1 million in 2022, then skyrocketed by 39.48% to $44.8 million in 2023, then surged by 51.68% to $67.9 million in 2024, then grew by 20.47% to $81.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $81.8 million for Q3 2025, versus $81.6 million for Q2 2025 and $81.3 million for Q1 2025.